Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. The focus of the current work is to evaluate known mutation carriers of the m.3243A\>G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement for participation). Paternal relatives will serve as controls. This study involves no treatment.
The purpose of this study is to investigate the neurological and biochemical consequences of the m.3243 A\>G mutation. Mitochondria are the powerhouses of the cell and are controlled by nuclear genetic material (DNA) and mitochondrial (mt) DNA. Mitochondrial DNA mutations impair mitochondrial function, and cause cellular energy failure. These mutations, when present in high abundance, cause neurological signs and symptoms that are clinically obvious. The investigators hypothesize that these mutations, when present in lesser abundance, will cause measurable alterations in the patient's neuropsychological profile and cerebral energy profile. This study does not involve any experimental or approved therapy. The investigators will evaluate the patient's condition with blood/urine tests, neurological exam, MRI/MRS, questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.
Study Type
OBSERVATIONAL
Enrollment
300
Columbia University
New York, New York, United States
RECRUITINGMRI/MRS
Evaluate structure and function in brain and muscle
Time frame: 2-3 years
Biomarkers
Evaluate various biomarkers of disease progression
Time frame: 2-3 years
Motor skills
6 minute walk test to evaluate motor skills
Time frame: 2-3 years
Cognitive function
Evaluate cognitive function through neuropsychological testing
Time frame: 2-3 years
Clinical symptoms
Evaluate clinical symptoms through medical history questionnaires and physical exam
Time frame: 2-3 years
Mutation load
Evaluate heteroplasmy through blood,urine and skin fibroblast evaluations
Time frame: 2-3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.